Antiplatelet therapy in ischemic stroke

References

• Brainin M, Olsen TS, Chamorro A et al., EUSI Executive Committee; EUSI Writing Committee. Organization of stroke care: education, referral, emergency management and imaging, stroke units and rehabilitation. European Stroke Initiative. Cerebrovasc. Dis. 17(Suppl. 2), 1–14 (2004).
   Google Scholar
• American Heart Association. Heart Disease and Stroke Statistics 2003 Update.Statistical Office of the European Communities. American Heart Association, TX, USA (2002).
   Google Scholar
• European Society of Hypertension/European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Report 2001. WHO, Geneva, Switzerland (2001).
   Google Scholar
• Hankey GJ, Warlow C. Treatment and secondary prevention of stroke: evidence, costs, and effects on individuals and populations. Lancet 354, 1457–1463 (1999).
   PubMed Web of Science ®Google Scholar
• Guillot F, Moulard O. Epidemiological estimates of ischaemic stroke and myocardial infarction. Circulation 98(Suppl. 1), 1421 (1998).
   Google Scholar
• Drouet L. Atherothrombosis as a systemic disease. Cerebrovasc. Dis. 13(Suppl. 1), 1–6 (2002).
   Google Scholar
• Schafer AI. Antiplatelet therapy. Am. J. Med. 101, 199–209 (1996).
   PubMed Web of Science ®Google Scholar
• Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 4, 252–261 (1993).
   PubMed Web of Science ®Google Scholar
• Kistler JP, Robber AH, Martin JB. Cerebrovascular diseases. In: Harrison’s Principles of Internal Medicine, 13th Edition. Isselbacher KJ, Braunwald E, Wilson J et al. (Eds), McGraw-Hill, NY, USA, 2240–2256 (1994).
   Google Scholar
• Fritzgerald GA. Drug therapy: dipyridamole. N. Engl. J. Med. 316, 1247–1257 (1987).
   Google Scholar
• Müller TH, Su CAPF, Weisenberger H et al. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole-blood ex vivo. Br. J. Clin. Pharmacol. 30, 179–86 (1990).
   PubMed Web of Science ®Google Scholar
• Harker LA, Bruno JJ. Ticlopidine’s mechanism of action on human platelets. In: Ticlopidine, Platelets and Vascular Disease. Hass WK, Easton JD (Eds). Springer, NY, USA, 41–59 (1993).
   Google Scholar
• Straub S, Junghans U, Jovanovic V, Wittsack HJ, Seitz RJ, Siebler M. Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in acute middle cerebral artery occlusion. Stroke 35(3), 705–709 (2004).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Diener HC, Bogousslavsky J, Brass LM et al. MATCH investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364(9431), 331–337 (2004).
   PubMed Web of Science ®Google Scholar
• de Gaetano G, Donati MB, Cerletti C. Prevention on thrombosis and vascular inflammation: benefits and limitations of selective or combined COX-1, COX-2 and 5-LOX inhibitors. Trends Pharmacol. Sci. 24, 245–252 (2003).
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br. Med. J. 308, 81–106 (1994).
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel. Efficacy, safety, and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol. 11, 1980–1987 (2004).
   Google Scholar
• Mason PJ, Freedman JE, Jacobs AK et al. Aspirin resistance: current concepts. Rev. Cardiovasc. Med. 5(3), 156–163 (2004).
   PubMedGoogle Scholar
• Grundmann K, Jaschonek K, Kleine B et al. Aspirin nonresponder status in patients with recurrent cerebral ischemic attacks. J. Neurol. 250, 63–66 (2003).
   PubMed Web of Science ®Google Scholar
• Pongracz E. Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke. Clin. Hemorheol. Microcirc. 30(3–4), 237–242 (2004).
   Google Scholar
• Eikelboom JW, Hirsh J, Weitz JI et al. Aspirin resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke and cardiovascular death in patients at high risk for cardiovascular events. Circulation 105, 1650–1655 (2002).
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Poggio ED et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol.88, 230–235 (2001).
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Weish PA et al. A prospective, blinded determination of the natural history of aspirin resistance among stabile patients with cardiovascular disease. J. Am. Coll. Cardiol. 41, 961–965 (2003).
   PubMed Web of Science ®Google Scholar
• Kiss RG, Kerecsen G, Rudas L et al. Aspirin and ticlopidine resistance in cardiovascular patients. Multicenter database of 2425 patients aimed to standardize the laboratory control of antiplatelet therapy. Eur. Heart J. 24, 371 (2003).
   Google Scholar
• Chen W-H, Lee P-Y, Ng W et al. Aspirin resistance is associated with a high incidence of myonecrosis after nonurgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43, 1122–1126 (2004).
   PubMed Web of Science ®Google Scholar
• Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin nonresponder. A pilot-study including 180 post-stroke patients. Thromb. Res. 71, 397–403 (1993).
   PubMed Web of Science ®Google Scholar
• Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am. J. Cardiol. 90, 893–895 (2002).
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V, Shechter M et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109, 3171–3175 (2004).
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(Suppl. 3), 234S–264S (2004).
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Malinin AI, Eisert MR, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am. J. Hematol. 75, 40–47 (2004).
   Google Scholar
• Mason PJ, Freedman JE, Jacobs AK et al. Aspirin resistance: current concepts. Rev. Cardiovasc. Med. 5(3), 156–163 (2004).
   PubMedGoogle Scholar
• Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke. Chest 119, 300S–320S (2001).
   Google Scholar
• Scheen AJ, Lefebvre PJ, Kulbertus H. Prevention of cardiovascular diseases using a combined pharmacologic approach: is there any place for a ‘polypill’? Rev. Med. Liege 58(9), 527–533 (2003).
   Google Scholar
• Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br. Med. J. 326(7404), 1419 (2003).
   PubMed Web of Science ®Google Scholar
• Nicholson NS, Panzer-Knodle SG, Haas NF et al. Assessment of platelet function assays. Am. Heart J.135, S170–S178 (1998).
   PubMed Web of Science ®Google Scholar
• Pongracz E, Bernat SI, Rudas L, Stef GY, Kiss RG. Resistance during antiplatelet therapy based on a multicenter database of ischaemic stroke and cardiovascular patients. Cerebrovasc. Dis. 17(Suppl. 5), 73 (2004).
   Google Scholar
• Homoncik M, Jilma B, Hergovich N et al. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb. Haemost. 82, 316–321 (2000).
   Google Scholar
• Wang JC, Aucoin-Barry D, Manuelian D et al. Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA. Am. J. Cardiol. 92, 1492–1494 (2003).
   PubMed Web of Science ®Google Scholar
• Freedman JE. CD40-CD40L and platelet function: beyond hemostasis. Circ. Res. 92, 944–946 (2003).
   PubMed Web of Science ®Google Scholar
• Chimowitz MI, Lynn JM, Howlett-Smith H et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 352, 1305–1316 (2005).
   PubMed Web of Science ®Google Scholar